Data from the Apple (AAPL) Heart Study presented this weekend at the American College of Cardiology conference highlighted the growing overlap of consumer-tech and healthcare, Canaccord Genuity analyst Jason Mills tells investors in a research note. He thinks the study "portends positively" for Irhythm Technologies (IRTC), initially from the standpoint that consumer wearable-generated awareness around atrial fibrillation should fuel interest in continuous monitoring devices like the company's Zio. Theh analyst points out that the patch used in the Apple Study, ePatch, detected atrial fibrillation in only 34% of patients who received and returned a monitoring patch after the Apple Watch detected an irregular rhythm. This contrasts to a positive predictive value of 84% in patients wearing the patch and watch simultaneously, suggesting ePatch missed a diagnosis in ~50% of patients, says Mills. The analyst believes these results underscore the value of Zio's continuous extended wear period versus competitive platforms in detecting arrhythmias. Mills views the growing consumer wearable market as a potential market expander for Zio and keeps a Buy rating on iRhythm with a $104 price target. The stock in late morning trading is up 2%, or $1.85, to $92.29.

Apple saw sales of its iPhones fall 19.1% in the first three months of the year, CNBC's Ryan Browne reports, citing data from Counterpoint Research. Meanwhile, Huawei saw a 69.7% surge in smartphone sales in the country during the same period, Counterpoint said. Reference Link